The final session of a turbulent week on Wall Street begins with a sense of calm and cautious optimism. Since the local low on March 31, the major US indices have already recovered about 9%, returning to levels seen before the start of the war in Iran, despite the lack of solid prospects for peace in the region. Today, most futures contracts on the main indices are hovering around opening levels, limiting gains to about 0.2%.
Even though oil prices remain close to the $100-per-barrel level, the market appears to be shifting its focus back toward the technology sector and AI.
At the same time, next week marks the official start of another earnings season. The financial sector will be first to report, on Monday we will see results from Goldman Sachs and FB Financial.
Macroeconomic data
The BLS released US (March) inflation data. In line with market expectations, price growth accelerated noticeably amid the Iran conflict, but the reading ultimately came in slightly below the market consensus. A clear difference can also be observed between headline and core inflation, indicating which consumption categories are the main contributors to rising prices.
- CPI inflation (YoY): 3.3% (expected: 3.4%; previous: 2.4%)
- Core CPI inflation (YoY): 2.6% (expected: 2.7%; previous: 2.5%)
US100 (D1)
The chart shows a fast and decisive return of buyer control after rebounding from the 23,000-point level. EMA moving averages are returning to bullish momentum, and the MACD is sending a clear bullish signal. The base-case scenario appears to be a test of 26,000 points; however, bulls should be mindful of a rising RSI. Source: xStation5
Company news
- CoreWeave (CRWV.US): The cloud infrastructure operator announced a partnership with Anthropic. One of the leading AI model developers is expected to lease computing power from the company. Shares are up about 3%.
- Lumentum Holdings (LITE.US): The company’s CEO spoke about strong demand for its solutions, driven by AI-related demand. The stock is up more than 2%.
- Nike (NKE.US): The apparel conglomerate received a negative recommendation from an investment firm. Shares are down about 1%.
- Palantir (PLTR.US): One of the leading AI solution providers for governments and large companies is posting another significant decline. The stock is falling mainly amid concerns about competition from Anthropic’s solutions.
- Organon (OGN.US): The pharmaceutical company is up more than 20% after Economic Times published an article reporting that Sun Pharmaceutical may acquire the company for $12 billion.
- CrowdStrike (CRWD.US) and Palo Alto (PANW.US): Both are falling again amid concerns about the capabilities of Anthropic’s “Claude Mythos” model.
Intel on a winning streak 📈
Globalstar: Are we headed for a battle of giants over orbit?
Intuitive Machines: Flywheel of the space economy?
Tesla disappoints with deliveries - Again
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
